BPC-157: A Comprehensive Research Overview

What Is BPC-157?

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide comprising 15 amino acids. It is derived from a protective protein found in human gastric juice and has been the subject of extensive preclinical research since the early 1990s.

Its molecular formula is C62H98N16O22 with a molecular weight of approximately 1,419.55 Da. Research-grade BPC-157 is supplied as a lyophilized (freeze-dried) white powder and is typically reconstituted with bacteriostatic water for in vitro and in vivo studies.

Proposed Mechanisms Under Investigation

Published research has proposed several mechanisms by which BPC-157 may exert its effects in laboratory models:

Nitric Oxide (NO) Pathway Modulation Multiple studies have examined BPC-157's interaction with the nitric oxide system. Researchers have observed that it may influence both eNOS (endothelial nitric oxide synthase) and nNOS (neuronal nitric oxide synthase) activity in animal models, which could relate to its observed effects on vascular and neurological endpoints.

Growth Factor Upregulation Preclinical data suggests BPC-157 may upregulate VEGF (vascular endothelial growth factor) expression, potentially contributing to angiogenesis and tissue vascularisation observed in wound-healing models.

Tendon and Ligament Fibroblast Activity Several studies using rat models have reported accelerated tendon-to-bone healing, with histological analyses showing increased fibroblast proliferation and collagen organisation in BPC-157-treated groups compared to controls.

Gastrointestinal Cytoprotection As a derivative of a gastric protein, BPC-157 has been studied extensively in GI models. Research has examined its effects on gastric ulcer healing, intestinal anastomosis repair, and inflammatory bowel disease models in rodents.

Key Published Studies

| Year | Authors | Model | Key Finding | |------|---------|-------|-------------| | 1993 | Sikiric et al. | Rat (gastric ulcer) | Accelerated mucosal healing vs. control | | 2001 | Pevec et al. | Rat (tendon transection) | Improved tendon-to-bone reattachment | | 2010 | Gjurasin et al. | Rat (peripheral nerve crush) | Functional recovery improvement | | 2014 | Sikiric et al. | Rat (spinal cord injury) | Reduced lesion volume, improved motor scores | | 2019 | Vukojevic et al. | Rat (traumatic brain injury) | Neuroprotective markers upregulated |

All studies cited are preclinical animal models. No human clinical trials for BPC-157 have been completed to date.

Purity and Quality Standards

For research applications, BPC-157 purity is critical to result reproducibility. Researchers should look for:

• HPLC purity ≥98% — High-Performance Liquid Chromatography is the gold standard for peptide purity verification
• Certificate of Analysis (COA) — Should include HPLC chromatogram, mass spectrometry confirmation, and endotoxin testing
• Lyophilized format — Freeze-dried powder is more stable during shipping and storage than pre-dissolved solutions
• CAS number verification — BPC-157 CAS: 137525-51-0

Pure Peptides supplies BPC-157 at ≥99.6% HPLC purity with a full COA available for every batch.

Storage and Handling

Lyophilized BPC-157 should be stored at -20°C and protected from light. Once reconstituted, solutions should be stored at 4°C and used within 28 days, or aliquoted and stored at -20°C for longer-term use. Avoid repeated freeze-thaw cycles.

Regulatory Status

BPC-157 is not approved by the FDA, EMA, or any regulatory authority for human use. It is classified as a research compound and is sold exclusively for in vitro and in vivo laboratory research purposes. It is not intended for human consumption, injection, or therapeutic application.

---

This article is for informational purposes only and does not constitute medical advice. All research must comply with applicable institutional and regulatory guidelines.